Evidence map›Paper›PMID 38892249›Full record

ReviewInternational journal of molecular sciences2024

Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options.

Debora B Mello, Fernanda Cristina Paccola Mesquita, Danúbia Silva Dos Santos, Karina Dutra Asensi, Marlon Lemos Dias, Antonio Carlos Campos de Carvalho, Regina Coeli Dos Santos Goldenberg, Tais Hanae Kasai-Brunswick

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Debora B MelloNational Center of Structural Biology and Bioimaging, CENABIO, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0002-2096-2907
Fernanda Cristina Paccola MesquitaRegenerative Medicine Research Department, The Texas Heart Institute, Houston, TX 77030, USA.ORCID 0000-0003-1038-010X
Danúbia Silva Dos SantosCenter of Cellular Technology, National Institute of Cardiology, INC, Rio de Janeiro 22240-002, Brazil.ORCID 0000-0002-7278-7143
Karina Dutra AsensiNational Institute of Science and Technology for Regenerative Medicine-REGENERA, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0002-8649-3226
Marlon Lemos DiasCarlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0001-9354-7280
Antonio Carlos Campos de CarvalhoNational Center of Structural Biology and Bioimaging, CENABIO, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0002-0062-3043
Regina Coeli Dos Santos GoldenbergNational Institute of Science and Technology for Regenerative Medicine-REGENERA, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0002-0886-9603
Tais Hanae Kasai-BrunswickNational Center of Structural Biology and Bioimaging, CENABIO, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0002-6361-5980

Funding

Coordination of Superior Level Staff Improvement - CAPES 00x0ma614Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/010.002457/2019, E-26/201.306/2021 and E-26/211.266/2021National Council for Scientific and Technological Development 465656/2014-5, 406161/2018-6 and 408200/2021-9National Institute of Science and Technology in Regenerative Medicine 465656/2014-5
6 · The paper itself

Abstract

Mesenchymal stromal cell (MSC)-based advanced therapy medicinal products (ATMPs) are being tried in a vast range of clinical applications. These cells can be isolated from different donor tissues by using several methods, or they can even be derived from induced pluripotent stem cells or embryonic stem cells. However, ATMP heterogeneity may impact product identity and potency, and, consequently, clinical trial outcomes. In this review, we discuss these topics and the need to establish minimal criteria regarding the manufacturing of MSCs so that these innovative therapeutics may be better positioned to contribute to the advancement of regenerative medicine.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationRegenerative MedicineAnimalsCell DifferentiationHumansInduced Pluripotent Stem Cellsadvanced therapy medicinal productsmesenchymal stromal cellregenerative medicine

Identifiers

PMID38892249
PMCPMC11173248

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.